December 8, 2017 Characterizing Disease Progression for Parkinson’s Disease to implement efficient trial designs
December 8, 2017 Model-Informed Biomarker Qualification: Alzheimer and Parkinson Disease Imaging Biomarkers
December 4, 2017 C-Path and FARA announce collaborative data aggregation project for Friedreich’s ataxia Tucson, AZ, and Downingtown, PA — December 4, 2017 — Critical Path Institute‘s (C-Path) Data Colla
December 1, 2017 Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy
November 25, 2017 Chronic Pulmonary Insufficiency of Prematurity: Developing Optimal Endpoints for Drug Development
November 16, 2017 FDA CDER Regulatory Science: The Importance of Partnership and Consortia Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research within the United States Food and Drug Administration,
November 1, 2017 FDA qualification of intracranial adjusted hippocampal volumetric magnetic resonance imaging (ICV-HV vMRI) as a prognostic biomarker for pre-dementia clinical trials for Alzheimer disease therapeutics Conrado, D.J., et al.; “FDA qualification of intracranial adjusted hippocampal volumetric magnetic resonance imaging (ICV-HV vMR
November 1, 2017 Informed consent ensuring access to anonymized patient-level data and biospecimen is critical to accelerating innovative Alzheimer disease treatments Arnerić, S.P., et al.; “Informed consent ensuring access to anonymized patient-level data and biospecimen is critical to accele
